UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Clinical meaningfulness of complete skin clearance in psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.77-82.e7

2016

Volltextzugriff (PDF)

The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

Journal of investigative dermatology, 2013-01, Vol.133 (1), p.17-26

2013

Volltextzugriff (PDF)

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1183-1190.e3

2014

Volltextzugriff (PDF)

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn's Disease: a Phase 2a Study

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.77-86.e6

2017

Volltextzugriff (PDF)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Journal of the American Academy of Dermatology, 2020-09, Vol.83 (3), p.839-846

2020

Volltextzugriff (PDF)

Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis

Journal of allergy and clinical immunology, 2020-03, Vol.145 (3), p.922-932

2020

Volltextzugriff (PDF)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Nature communications, 2022-08, Vol.13 (1), p.4931-4931, Article 4931

2022

Volltextzugriff (PDF)

Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease Control

Chest, 2015-12, Vol.148 (6), p.1489-1496

2015

Volltextzugriff (PDF)

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Journal of the American Academy of Dermatology, 2012-07, Vol.67 (1), p.86-92

2012

Volltextzugriff (PDF)

Contrasting Roles of the IL-1 and IL-18 Receptors in MyD88-Dependent Contact Hypersensitivity

Journal of investigative dermatology, 2010-01, Vol.130 (1), p.184-191

2010

Volltextzugriff (PDF)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Nature communications, 2023-01, Vol.14 (1), p.333-333, Article 333

2023

Volltextzugriff (PDF)

Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology, 2015-03, Vol.72 (3), p.436-439.e1

2015

Volltextzugriff (PDF)

Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis

Value in health, 2017-09, Vol.20 (8), p.1174-1179

2017

Volltextzugriff (PDF)

Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole

Journal of the American Academy of Dermatology, 2009-04, Vol.60 (4), p.589-594

2009

Volltextzugriff (PDF)

Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment

Pathogens & immunity, 2024-08, Vol.9 (2), p.58-78

2024

Volltextzugriff (PDF)

Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice

The Journal of dermatological treatment, 2016-05, Vol.27 (3), p.224-227

2016

Volltextzugriff (PDF)

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

JCI insight, 2022-12, Vol.7 (24)

2022

Volltextzugriff (PDF)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

The New England journal of medicine, 2021-10, Vol.385 (15), p.1382-1392

2021

Volltextzugriff (PDF)

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

The New England journal of medicine, 2021-03, Vol.384 (10), p.905-914

2021

Volltextzugriff (PDF)

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

The New England journal of medicine, 2021-01, Vol.384 (3), p.229-237

2021

Volltextzugriff (PDF)

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-02, Vol.325 (7), p.632

2021

Volltextzugriff (PDF)

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

The New England journal of medicine, 2015-10, Vol.373 (14), p.1318-1328

2015

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease

The American journal of gastroenterology, 2016-11, Vol.111 (11), p.1599-1607

2016

Volltextzugriff (PDF)

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2020-02, Vol.158 (3), p.537-549.e10

2020

Volltextzugriff (PDF)

Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells

The Journal of experimental medicine, 2010-04, Vol.207 (4), p.823-836

2010

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(65)
Dissertationen
(1)

Sprache

Englisch
(66)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(36)
Humans
(30)
Adult
(23)
Female
(22)
Male
(21)
Middle Aged
(19)
Dermatology
(17)
Double-Blind Method
(14)
Severity Of Illness Index
(14)
Covid-19
(12)
Monoclonal Antibodies
(12)
Psoriasis - Drug Therapy
(11)
Aged
(9)
Treatment Outcome
(9)
Antibodies, Monoclonal - Therapeutic Use
(8)
Severe Acute Respiratory Syndrome Coronavirus 2
(8)
Biological And Medical Sciences
(7)
Brodalumab
(7)
Coronaviruses
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical meaningfulness of complete skin clearance in psoriasis

The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn's Disease: a Phase 2a Study

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease Control

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Contrasting Roles of the IL-1 and IL-18 Receptors in MyD88-Dependent Contact Hypersensitivity

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis

Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis

Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole

Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment

Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells

Suchergebnisse filtern